Phetharbital
Chemical compound
- none
- 1-Phenyl-5,5-diethyl-1,3-diazinane-2,4,6-trione
- 357-67-5
Y
- 9650
- 9271
N
- 52HG53W51E
- DTXSID30189216
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- c2ccccc2N(C1=O)C(=O)NC(=O)C1(CC)CC
InChI
- InChI=1S/C14H16N2O3/c1-3-14(4-2)11(17)15-13(19)16(12(14)18)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3,(H,15,17,19)
N
- Key:ILORKHQGIMGDFN-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Phetharbital (phenetharbital) is a barbiturate derivative. It has anticonvulsant effects and relatively weak sedative action, and is considered to have a low abuse potential.[1]
References
- ^ Eddy NB, Halbach H, Isbell H, Seevers MH (1965). "Drug dependence: Its significance and characteristics". Bulletin of the World Health Organization. 32 (5): 721–733. PMC 2555251. PMID 5294186.
- v
- t
- e
Anticonvulsants (N03)
GABAAR PAMs |
|
---|---|
GABA-T inhibitors |
|
Others |
modulators
CA inhibitors |
|
---|---|
Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e